Unknown

Dataset Information

0

Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine.


ABSTRACT: Agents that block insulin-like growth factor (IGF) signaling are under investigation in clinical trials. Antitumor effects are likely to be enhanced when combined with other agents, but administration sequence effects on activity are not well-described. Three breast cancer cell lines (MCF-7, MDA-MB-231, and Hs-578T) were treated with Gemcitabine and small molecule receptor tyrosine kinase inhibitor cis-3-[3-(4-methyl-piperazin-l-yl)-cyclobutyl]1-(2-phenyl-quinolin-7-yl)-imidazo [1,5-a]pyrazin-8-ylamine (PQIP) as single agents and then in combination in the forward (Gemcitabine followed by PQIP) and reverse (PQIP followed by Gemcitabine) sequences. Antitumor effects were assessed longitudinally by Bayesian analysis using WinBUGS. The pharmacodynamic model adequately predicted the observed data. The differences in the cell-kill rate constants for the forward vs. reverse sequence ranged from 0.11 to 0.64 (day(-1)), and statistical significance was generally dependent on cell line and PQIP concentration. These data indicate that treatment with Gemcitabine first, followed by PQIP is superior to the reverse sequence in vitro.

SUBMITTER: Khatri A 

PROVIDER: S-EPMC3291184 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine.

Khatri Amit A   Brundage Richard C RC   Hull Jessica M JM   Williams Brent W BW   Yee Douglas D   Kirstein Mark N MN  

The AAPS journal 20111119 1


Agents that block insulin-like growth factor (IGF) signaling are under investigation in clinical trials. Antitumor effects are likely to be enhanced when combined with other agents, but administration sequence effects on activity are not well-described. Three breast cancer cell lines (MCF-7, MDA-MB-231, and Hs-578T) were treated with Gemcitabine and small molecule receptor tyrosine kinase inhibitor cis-3-[3-(4-methyl-piperazin-l-yl)-cyclobutyl]1-(2-phenyl-quinolin-7-yl)-imidazo [1,5-a]pyrazin-8-  ...[more]

Similar Datasets

| S-EPMC4284963 | biostudies-literature
| S-EPMC3488689 | biostudies-literature
| S-EPMC5108803 | biostudies-literature
| S-EPMC3079196 | biostudies-other
| S-EPMC4593065 | biostudies-literature
| S-EPMC6975273 | biostudies-literature
| S-EPMC1217607 | biostudies-other
2012-12-13 | E-GEOD-42864 | biostudies-arrayexpress
| S-EPMC3237768 | biostudies-literature
| S-EPMC9364964 | biostudies-literature